Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 5/20 | 0.36 |
| ▸ | GNAI3 | P08754 | 4/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 4/20 | 0.34 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21911443 | 0.94 | GNAO1 (0.34) | GNAO1GNAI3GNAI1SMYD3 | |
| SCHEMBL18648899 | 0.90 | SMYD3 (0.35) | SMYD3 | |
| SCHEMBL18922637 | 0.77 | GNAI3 (0.31) | GNAO1GNAI3GNAI1 | |
| SCHEMBL23961354 | 0.76 | GNAO1 (0.32) | GNAO1GNAI3GNAI1 | |
| SCHEMBL18074011 | 0.76 | PIK3CD (0.45) | SMN1; SMN2 | |
| SCHEMBL9976596 | 0.76 | PIK3CD (0.45) | SMN1; SMN2 | |
| SCHEMBL6613727 | 0.75 | SMYD3 (0.37) | GNAO1SMYD3SMN1; SMN2 | |
| SCHEMBL26296782 | 0.73 | CCL5 (0.31) | — | |
| SCHEMBL26287164 | 0.73 | CCL5 (0.31) | — | |
| SCHEMBL24950281 | 0.72 | SMN1; SMN2 (0.42) | GNAO1GNAI3GNAI1SMYD3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10676433-B2 | Indole derivatives and their use in neurodegenerative diseases | MERCK PATENT GMBH (DE) | 2020-06-09 | — | — | US | disclosed |
| US-20190161447-A1 | NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2019-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190161447-A1 | NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | P2RX3, P2RX7, P2RX2 | GNAO1 806/4885GNAI3 990/4885GNAI1 1105/4885 |
| US-10676433-B2 | Indole derivatives and their use in neurodegenerative diseases | P2RX3, ADORA2A, P2RX7 | GNAO1 830/4885GNAI3 783/4885GNAI1 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.